常用PPI治疗反流性食管炎的临床疗效与药物经济学分析

The Curative Effect and the Pharmacoeconomics of the PPI Treatment RE

目的探讨临床常用抑酸药治疗RE的临床疗效及其药物经济学分析。方法按诊断标准选取我院300例反流性食管炎患者,随机分为奥美拉唑组、雷贝拉唑组、埃索美拉唑组、泮托拉唑组、兰索拉唑组各60例,比较5组所用抑酸剂的临床疗效及其药物经济学分析。结果 5组8周后症状降低总有效率分别为90.5%、99.8%、98.3%、87.5%、89.8%;内镜下检查表现总有效率分别为91.7%、100.0%、98.3%、86.7%、90.0%;治疗成本分别为605.6、1498.5、1932.6、895.6、907.5元;成本-效果比分别为6.6、15.0、19.4、10.3及10.1;雷贝拉唑疗效最好而奥美拉唑成本最低。结论在治疗RE时可根据患者个体以及经济状况的特殊性选择其最适合的药物,若患者经济条件允许可选择新一代抑酸药如雷贝拉唑,而传统抑酸药如奥美拉唑因更经济而适用于广大基层医院患者治疗。

Objective To explore the curative effect of the PPI clinical commonly used in the treatment of RE and its pharmacoeconomics analysis. Methods According to the selection criteria for the diagnosis of 300 cases of the RE patients were randomly divided into Omeprazole group, Rabeprazole group, Esomeprazole Pantoprazoleroup, Lansoprazole group, each of 60 cases. To compare these 5 groups of the curative effect of the PPI clinical commonly used in the treatment of RE and its pharmacoeconomics analysis. Results Rabeprazole group symptoms reduced the total effective rate was the largest of each 90.5%,99.8%,98.3%,87.5%, 89.8% and 91.7%, 100.0%,98.3%,86.7%,90.0% respectively, while Omeprazole group＇s costs-ratio was the minimum as 605.6, 1498.5.1932.6,895.6. 907.5 Yuan and 6.6, 15.0,19.4,10.3.10.1 respectively. Conclusion In the treatment of RE, we should according to individual patients and the particularity of the economic situation choose the most suitable for drugs, if economic conditions allow patients to choose a new generation of PPI such as Rabeprazole, but the traditional PPI such as Omeprazolefor indicates much more economic welcomed.